drugset / Trial / NCT03253133
Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC
NaSingle-groupOpen-labelTreatment
Summary
This study determine the maximal tolerate dose
Timeline
- Start
- 2016-05-10
- Primary completion
- 2020-10-28
- Completion
- 2023-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 70 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 160 mg/m2 | Other |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxycodone | Other / unclassified | — | — |
| Background | fluorouracil | Small molecule | — | — |